{"title":"Network Pharmacology Analysis and Experimental Verification of Weinaian Capsule for Treating Gastric Cancer.","authors":"Qisheng Cheng, Xinghua Li, Lujun Shen, Ting Yang","doi":"10.2174/0113892010365834250418065923","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Traditional Chinese medicine has been widely used to treat gastric cancer, but the effect of the Weinaian capsule on gastric cancer is still unclear.</p><p><strong>Objective: </strong>This study aimed to find the potential therapeutic targets and pharmacological mechanisms of Weinaian capsule in gastric cancer.</p><p><strong>Methods: </strong>We employed the network pharmacological analysis to find the therapeutic targets. Firstly, we searched the bioactive components of Weinaian capsule in TCMSP and the Swiss database. We downloaded disease gastric cancer targets from the GeneCards database and used the Venn diagram to identify common targets for disease and drugs. Then, we performed GO and KEGG pathway enrichment analyses, used the Cytoscape software to screen core targets and components, and constructed a drug-disease-target network. In addition, visual molecular docking and molecular dynamics simulation of targets and components with strong affinity were performed. Finally, we verified the effect of the drug on cell proliferation and metastasis using CCK8, clonal formation, and wound healing assays, and investigated the molecular mechanism by qRT-PCR.</p><p><strong>Results: </strong>A total of 33 bioactive components were procured; 128 common targets for gastric cancer and drugs were screened. The GO and KEGG pathway enrichment analyses showed the PI3K-AKT pathway to be at the top. The core target AKT1 and the core component isorhamnetin exhibited the strongest molecular binding force and good binding stability. Compared to the control group, Weinaian capsule group inhibited gastric cancer cell proliferation and migration by down-regulating the expressions of PI3K and AKT.</p><p><strong>Conclusion: </strong>Weinaian capsule inhibited cell proliferation and metastasis by affecting the PI3K-AKT pathway in gastric cancer.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010365834250418065923","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Traditional Chinese medicine has been widely used to treat gastric cancer, but the effect of the Weinaian capsule on gastric cancer is still unclear.
Objective: This study aimed to find the potential therapeutic targets and pharmacological mechanisms of Weinaian capsule in gastric cancer.
Methods: We employed the network pharmacological analysis to find the therapeutic targets. Firstly, we searched the bioactive components of Weinaian capsule in TCMSP and the Swiss database. We downloaded disease gastric cancer targets from the GeneCards database and used the Venn diagram to identify common targets for disease and drugs. Then, we performed GO and KEGG pathway enrichment analyses, used the Cytoscape software to screen core targets and components, and constructed a drug-disease-target network. In addition, visual molecular docking and molecular dynamics simulation of targets and components with strong affinity were performed. Finally, we verified the effect of the drug on cell proliferation and metastasis using CCK8, clonal formation, and wound healing assays, and investigated the molecular mechanism by qRT-PCR.
Results: A total of 33 bioactive components were procured; 128 common targets for gastric cancer and drugs were screened. The GO and KEGG pathway enrichment analyses showed the PI3K-AKT pathway to be at the top. The core target AKT1 and the core component isorhamnetin exhibited the strongest molecular binding force and good binding stability. Compared to the control group, Weinaian capsule group inhibited gastric cancer cell proliferation and migration by down-regulating the expressions of PI3K and AKT.
Conclusion: Weinaian capsule inhibited cell proliferation and metastasis by affecting the PI3K-AKT pathway in gastric cancer.
期刊介绍：
Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include:
DNA/protein engineering and processing
Synthetic biotechnology
Omics (genomics, proteomics, metabolomics and systems biology)
Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes)
Drug delivery and targeting
Nanobiotechnology
Molecular pharmaceutics and molecular pharmacology
Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes)
Pharmacokinetics and pharmacodynamics
Applied Microbiology
Bioinformatics (computational biopharmaceutics and modeling)
Environmental biotechnology
Regenerative medicine (stem cells, tissue engineering and biomaterials)
Translational immunology (cell therapies, antibody engineering, xenotransplantation)
Industrial bioprocesses for drug production and development
Biosafety
Biotech ethics
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
